What is the price-to-earnings ratio of PharmAbcine?
The price-earnings ratio of PharmAbcine is currently -5.66.
As of Oct 7, 2024, PharmAbcine's P/E ratio was -5.66, a 19.92% change from the -4.72 P/E ratio recorded in the previous year.
The Price to Earnings (P/E) Ratio of PharmAbcine is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Assessing PharmAbcine's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
The P/E ratio of PharmAbcine is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Fluctuations in PharmAbcine’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
The price-earnings ratio of PharmAbcine is currently -5.66.
The price-to-earnings ratio of PharmAbcine has increased by 19.92% increased compared to last year.
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Yes, the price-to-earnings ratio of PharmAbcine is high compared to other companies.
An increase in the price-earnings ratio of PharmAbcine would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
A decrease in the price-earnings ratio of PharmAbcine would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
Some factors that influence the price-earnings ratio of PharmAbcine are the company's growth, financial position, industry development, and the overall economic situation.
Over the past 12 months, PharmAbcine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PharmAbcine is expected to pay a dividend of 0 KRW.
The current dividend yield of PharmAbcine is .
PharmAbcine pays a quarterly dividend. This is distributed in the months of .
PharmAbcine paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
PharmAbcine is assigned to the 'Health' sector.
To receive the latest dividend of PharmAbcine from 10/7/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.
The last dividend was paid out on 10/7/2024.
In the year 2023, PharmAbcine distributed 0 KRW as dividends.
The dividends of PharmAbcine are distributed in KRW.
Our stock analysis for PharmAbcine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmAbcine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.